As China embraces AI, only 24% of US pharma execs bet on it for drug-making - South China Morning Post

While China's pharmaceutical industry is investing heavily in AI for drug development, only a quarter of US pharmaceutical executives say they're betting on AI for the same purpose. This gap suggests American pharma may be falling behind in adopting AI to speed up and lower the cost of creating new medicines.